Search Results 241-250 of 5979 for albumin

1. A Study to Evaluate Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer - Mayo Clinic

   ... albumin ≥ 3.0 g/dL;; Hepatic function for subjects with liver metastases: bilirubin ≤ 1.5 × ULN, AST, ALT, and GGT ≤ 5.0 × ULN, and albumin ≥ 3.0 g/dL.

2. Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma (SEQUEL) - Mayo Clinic

   * Albumin \> 3.0 g/dL * Females of childbearing potential must have a negative pregnancy test within 72 hours prior to registration. If the urine test is ...

3. A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients with Low-Grade Glioma - Mayo Clinic

   Albumin ≥ 2 g/dL. Left ventricular ejection fraction (LVEF) ≥ 53% (or institutional normal; if the LVEF result is given as a range of values, then the ...

4. Clinical Biochemistry & Immunology - Laboratory Medicine and Pathology

   Clinical Biochemistry & Immunology provides analysis of biological fluids or tissues for specific chemical constituents or physiologic processes.

5. A Study of Using Lorvotuzumab Mertansine in Treating Younger Patients with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma - Mayo Clinic

   Serum albumin ≥ 2 g/dL; Shortening fraction of ≥ 27% by echocardiogram, or ejection fraction of ≥ 50% by gated radionuclide study; Patients with seizure ...

6. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and Combined with Chemotherapy or Tislelizumab to Treat Patients with Metastatic Solid Tumors - Mayo Clinic

   albumin ≥ 3.0 g/dL;; international normalized ratio (INR) and partial thromboplastin time (PTT);; ≤ 1.5 x ULN;; amylase and lipase ≤ 1.5 x ULN. No evidence ...

7. Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer - Mayo Clinic

   ... albumin <3 mg/dL; History of severe allergy or intolerance to contrast agents, narcotics sedatives or atropine that cannot be managed medically ...

8. Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) - Mayo Clinic

   Another kidney biopsy will not be required as part of the study. Candidates must have failed or be intolerant of prior therapy for their kidney disease. The ...

9. Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors - Mayo Clinic

   Albumin ≥ 3.0 g/dL. Concurrent somatostatin analog use while on protocol therapy is allowed provided that the patient: Has a functional tumor (evidence of ...

10. Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid - Mayo Clinic

    Albumin <3.5 g/dL; Presence of clinical complications of PBC or clinically significant hepatic decompensation, including: Current Model for End-Stage Liver ...